p53 N‑terminal binding and stabilisation by PIAS3 inhibits MDM2‑induced p53 ubiquitination and regulates cell growth

Zhao,Ziyi; Wu,Lan; Shi,Huimin; Wu,Chuanfang

doi:10.3892/mmr.2014.1993

p53 N‑terminal binding and stabilisation by PIAS3 inhibits MDM2‑induced p53 ubiquitination and regulates cell growth

Authors:
- Ziyi Zhao
- Lan Wu
- Huimin Shi
- Chuanfang Wu
View Affiliations

Affiliations: Key Laboratory of Bioresources and Ecoenvironment, Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, Sichuan 610064, P.R. China
Published online on: February 27, 2014 https://doi.org/10.3892/mmr.2014.1993
Pages: 1903-1908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mouse double minute 2 homolog (MDM2) binds to p53 through the 1‑52 amino acid region of p53, in order to ubiquitinate p53. MDM2 thus destabilises p53 and inhibits the effect of p53 on cell cycle arrest and apoptosis. In the present study, the 1‑52 amino acid region of the wild‑type (wt) p53 protein was stably expressed in H1299 cells. The lysate of the transfected cells was then analysed using co‑immunoprecipitation. A specific fraction of the precipitate was subjected to mass spectrometry analysis, which revealed that p53 bound to protein inhibitor of activated STAT3 (PIAS3). To the best of our knowledge, the present study is the first to report that the interaction of PIAS3 with p53 occurs through the 1‑52 amino acid region of p53. Overexpression of PIAS3 in the A549 wt p53‑expressing cell line was found to significantly increase the half‑life of p53 in the presence of cycloheximide, an inhibitor of protein synthesis. However, PIAS3 overexpression did not affect p53 mRNA levels. Furthermore, PIAS3 overexpression was observed to decrease p53 ubiquitination. Protein‑protein interaction analysis revealed that PIAS3 binds to the 1‑52 amino acid region of p53, thus disrupts the formation of the p53‑MDM2 complex. In addition, overexpression of PIAS3 in A549 cells was found to enhance the transcription of the p53‑transactivated target p21/waf1, due to p53 accumulation, which led to an increase in p53 binding to the p21 gene promoter. These findings indicate that this newly identified p53‑PIAS3 interaction through the 1‑52 amino acid region of p53, reduces p53‑MDM2 complex formation, which not only increases the half‑life of p53, but also its transactivation of target genes.

View Figures

View References

1	Shaper NJ, Harrison M and Bates T: Impact of laparoscopic cholecystectomy on surgical training. Ann R Coll Surg Engl. 78:39–42. 1996.PubMed/NCBI
2	Evans SC and Lozano G: The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today. 3:390–395. 1997. View Article : Google Scholar : PubMed/NCBI
3	Attardi LD and Jacks T: The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci. 55:48–63. 1999. View Article : Google Scholar : PubMed/NCBI
4	Choi J and Donehower LA: p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci. 55:38–47. 1999. View Article : Google Scholar : PubMed/NCBI
5	Piette J, Neel H and Maréchal V: Mdm2: keeping p53 under control. Oncogene. 15:1001–1010. 1997. View Article : Google Scholar : PubMed/NCBI
6	Karanicolas J and Brooks CL III: The structural basis for biphasic kinetics in the folding of the WW domain from a forming-binding protein: Lessons for protein design? Proc Natl Acad Sci USA. 100:3954–3959. 2003. View Article : Google Scholar : PubMed/NCBI
7	Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ and Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274:948–953. 1996. View Article : Google Scholar : PubMed/NCBI
8	Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
9	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
10	Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA. 95:8292–8297. 1998. View Article : Google Scholar : PubMed/NCBI
11	Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C and DePinho RA: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell. 92:713–723. 1998.PubMed/NCBI
12	Honda R and Yasuda H: Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18:22–27. 1999. View Article : Google Scholar : PubMed/NCBI
13	Tao W and Levine AJ: P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA. 96:6937–6941. 1999. View Article : Google Scholar : PubMed/NCBI
14	Weber JD, Taylor LJ, Roussel MF, Sherr CJ and Bar-Sagi D: Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1:20–26. 1999. View Article : Google Scholar : PubMed/NCBI
15	Shadfan M, Lopez-Pajares V and Yuan ZM: MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res. 1:88–89. 2012.PubMed/NCBI
16	Chen J, Marechal V and Levine AJ: Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol. 13:4107–4114. 1993.PubMed/NCBI
17	Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
18	Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J and el-Deiry WS: The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther. 1:47–55. 2002. View Article : Google Scholar : PubMed/NCBI
19	el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
20	Martin K, Trouche K, Hagemeier C, Sørensen TS, La Thangue NB and Kouzarides T: Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 375:691–694. 1995. View Article : Google Scholar : PubMed/NCBI
21	Lughran O and La Thangue NB: Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol. 20:2186–2197. 2000. View Article : Google Scholar : PubMed/NCBI
22	Grossman SR, Perez M, Kung AL, et al: P300/MDM2 complexes participate in Mdm2-mediated p53 degradation. Mol Cell. 2:405–415. 1998. View Article : Google Scholar : PubMed/NCBI
23	Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K: Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89:1175–1184. 1997. View Article : Google Scholar : PubMed/NCBI
24	Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997. View Article : Google Scholar : PubMed/NCBI
25	Yu ZK, Geyer RK and Maki CG: MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogen. 19:5892–5897. 2000. View Article : Google Scholar : PubMed/NCBI
26	Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 275:8945–8951. 2000. View Article : Google Scholar : PubMed/NCBI
27	Geyer RK, Yu ZK and Maki CG: The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2:569–573. 2000. View Article : Google Scholar : PubMed/NCBI
28	Xirodimas DP, Stephen CW and Lane DP: Compartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res. 270:66–77. 2001. View Article : Google Scholar : PubMed/NCBI
29	Barak Y, Juven T, Haffner R and Oren M: Mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461–468. 1993.PubMed/NCBI
30	Durocher D and Jackson SP: DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol. 13:225–231. 2001. View Article : Google Scholar : PubMed/NCBI
31	Chehab NH, Malikzay A, Stavridi ES and Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA. 96:13777–13782. 1999. View Article : Google Scholar : PubMed/NCBI
32	Dumaz N, Milne DM, Jardine LJ and Meek DW: Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem J. 359:459–464. 2001. View Article : Google Scholar : PubMed/NCBI
33	Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M and Haupt Y: Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18:1805–1814. 1999. View Article : Google Scholar : PubMed/NCBI
34	Stindt MH, Carter S, Vigneron AM, Ryan KM and Vousden KH: MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle. 10:3176–3188. 2001. View Article : Google Scholar : PubMed/NCBI
35	Lee SW, Lee MH, Park JH, Kang SH, Yoo HM, Ka SH, Oh YM, Jeon YJ and Chung CH: SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO J. 31:4441–4452. 2012. View Article : Google Scholar : PubMed/NCBI
36	Lin J, Chen J, Elenbaas B and Levine AJ: Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1235–1246. 1994. View Article : Google Scholar : PubMed/NCBI
37	Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A and Prives C: The C-terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 17:982–989. 2010. View Article : Google Scholar : PubMed/NCBI